Literature DB >> 20954841

Combination of intra-bone marrow-bone marrow transplantation and subcutaneous donor splenocyte injection diminishes risk of graft-versus-host disease and enhances survival rate.

Ming Shi1, Yasushi Adachi, Yunze Cui, Ming Li, Zhexiong Lian, Yuming Zhang, Seiji Yanai, Chieko Shima, Yuichiro Imai, Susumu Ikehara.   

Abstract

The combination of allogeneic bone marrow transplantation (allo-BMT) and donor lymphocyte infusion (DLI) is a useful method for establishing donor chimerism and preventing a relapse of leukemia/lymphoma. However, there is a risk of inducing uncontrollable fatal graft-versus-host disease (GVHD). In fact, allo-BMT plus intravenous (IV)-DLI using donor splenocytes induces fatal GVHD in recipient mice. In this study, we examined the effects of the combination of intra-bone marrow (IBM)-BMT and the subcutaneous injection of donor splenocytes (SC-DLI) on the allo-BMT system. Recipient BALB/c mice were conditioned by sublethal irradiation (5 Gy), followed by IBM-BMT plus IV-DLI or SC-DLI in C57BL/6 mice. The IV-DLI group showed better engraftment of donor hemopoietic cells than the control group (without DLI) but showed fatal GVHD. The SC-DLI group, however, showed good reconstitution and mild GVHD. These results suggest that the combination of SC-DLI and IBM-BMT promotes the reconstitution of hemopoiesis and helps reduce the risk of GVHD.

Entities:  

Mesh:

Year:  2010        PMID: 20954841      PMCID: PMC3128777          DOI: 10.1089/scd.2010.0232

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  37 in total

1.  Allogeneic bone marrow transplantation (BMT) for refractory Behçet's disease with severe CNS involvement.

Authors:  A M Marmont; F Gualandi; G Piaggio; M Podestà; M Teresa van Lint; A Bacigalupo; F Nobili
Journal:  Bone Marrow Transplant       Date:  2006-06       Impact factor: 5.483

2.  A new bone marrow transplantation method for stem cell disorders.

Authors:  Susumu Ikehara
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

3.  Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer.

Authors:  Marco Bregni; Anna Dodero; Jacopo Peccatori; Alessandra Pescarollo; Massimo Bernardi; Isabella Sassi; Claudia Voena; Alberto Zaniboni; Claudio Bordignon; Paolo Corradini
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

4.  Target antigens determine graft-versus-host disease phenotype.

Authors:  Daniel H Kaplan; Britt E Anderson; Jennifer M McNiff; Dhanpat Jain; Mark J Shlomchik; Warren D Shlomchik
Journal:  J Immunol       Date:  2004-11-01       Impact factor: 5.422

5.  Intra-bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice.

Authors:  T Kushida; M Inaba; H Hisha; N Ichioka; T Esumi; R Ogawa; H Iida; S Ikehara
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

Review 6.  Stem cell transplantation for autoimmune diseases: what can we learn from experimental models?

Authors:  Susumu Ikehara
Journal:  Autoimmunity       Date:  2008-12       Impact factor: 2.815

7.  Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism.

Authors:  Markus Y Mapara; Yong-Mi Kim; Julie Marx; Megan Sykes
Journal:  Transplantation       Date:  2003-07-27       Impact factor: 4.939

8.  Efficacy of etoposide, cyclophosphamide, and total body irradiation in allogeneic bone marrow transplantation for adult patients with hematological malignancies.

Authors:  Tomomi Toubai; Junji Tanaka; Akio Mori; Satoshi Hashino; Sumiko Kobayashi; Shuichi Ota; Yoko Miura; Naoko Kato; Kaoru Kahata; Ko Izumiyama; Masakatu Yonezumi; Koji Chiba; Takeshi Kondo; Nobuyasu Toyoshima; Masahiro Asaka; Masahiro Imamura
Journal:  Clin Transplant       Date:  2004-10       Impact factor: 2.863

Review 9.  Hematopoietic cell transplantation for tolerance induction: animal models to clinical trials.

Authors:  Megan Sykes
Journal:  Transplantation       Date:  2009-02-15       Impact factor: 4.939

10.  In vivo imaging of graft-versus-host-disease in mice.

Authors:  Angela Panoskaltsis-Mortari; Andrew Price; John R Hermanson; Elizabeth Taras; Chris Lees; Jonathan S Serody; Bruce R Blazar
Journal:  Blood       Date:  2004-01-08       Impact factor: 22.113

View more
  5 in total

1.  CD4+ T cell-depleted lymphocyte infusion impairs neither the recovery of recipient thymus nor the development of transplanted thymus.

Authors:  Ming Shi; Ming Li; Yunze Cui; Lin Liu; Yasushi Adachi; Susumu Ikehara
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

2.  Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease.

Authors:  Wei Du; Nicholas D Leigh; Guanglin Bian; Rachel E O'Neill; Lin Mei; Jingxin Qiu; George L Chen; Theresa Hahn; Hong Liu; Philip L McCarthy; Xuefang Cao
Journal:  J Immunol       Date:  2015-09-21       Impact factor: 5.422

Review 3.  Intractable diseases treated with intra-bone marrow-bone marrow transplantation.

Authors:  Ming Li; Kuquan Guo; Susumu Ikehara
Journal:  Front Cell Dev Biol       Date:  2014-09-02

4.  Regional Intraosseous Administration of Prophylactic Antibiotics is More Effective Than Systemic Administration in a Mouse Model of TKA.

Authors:  Simon W Young; Tim Roberts; Sarah Johnson; James P Dalton; Brendan Coleman; Siouxsie Wiles
Journal:  Clin Orthop Relat Res       Date:  2015-07-30       Impact factor: 4.176

5.  Third-party regulatory T cells prevent murine acute graft-versus-host disease.

Authors:  Jung-Yeon Lim; Keon-Il Im; Yunejin Song; Nayoun Kim; Young-Sun Nam; Young-Woo Jeon; Seok-Goo Cho
Journal:  Korean J Intern Med       Date:  2017-10-19       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.